Catalyst Biosciences (CBIO) Receives News Sentiment Score of 0.31

Media headlines about Catalyst Biosciences (NASDAQ:CBIO) have been trending positive on Tuesday, AlphaOne Sentiment reports. The research group, a division of Accern, rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalyst Biosciences earned a news sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also gave press coverage about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.

Insider Buying and Selling by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Shares of Catalyst Biosciences (CBIO) traded down 0.4908% during midday trading on Tuesday, hitting $4.3386. The stock had a trading volume of 6,974 shares. Catalyst Biosciences has a 12-month low of $3.64 and a 12-month high of $30.00. The company’s 50-day moving average price is $4.31 and its 200-day moving average price is $6.98. The firm’s market cap is $18.48 million.

Catalyst Biosciences (NASDAQ:CBIO) last issued its quarterly earnings results on Thursday, May 11th. The biopharmaceutical company reported ($4.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($5.14) by $0.57. The company had revenue of $0.27 million for the quarter. Catalyst Biosciences had a negative return on equity of 95.60% and a negative net margin of 2,961.29%. Equities research analysts forecast that Catalyst Biosciences will post ($5.52) EPS for the current year.

A number of equities analysts have recently weighed in on CBIO shares. Chardan Capital started coverage on Catalyst Biosciences in a report on Monday, June 12th. They issued a “buy” rating and a $10.00 price target for the company. Ladenburg Thalmann Financial Services assumed coverage on Catalyst Biosciences in a report on Tuesday, June 6th. They issued a “buy” rating and a $11.00 price target for the company. Finally, Zacks Investment Research downgraded Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, June 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $26.55.

TRADEMARK VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/2655234/catalyst-biosciences-cbio-receives-news-sentiment-score-of-0-31.html.

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CBIO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.